BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Infectious disease

...peptide variants in animal models of bacterial infection. Alopexx Pharmaceuticals LLC and partner Sanofi have SAR279356...
BioCentury | Nov 10, 2014
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...Alopexx agreed to terminate a 2009 deal under which Sanofi gained exclusive, worldwide rights to SAR279356...
...poly-N-acetyl glucosamine (PNAG) . According to clinicaltrials.gov, a Sanofi-sponsored Phase II trial of SAR279356 (formerly F598...
BioCentury | Jun 13, 2013
Targets & Mechanisms

PNAG: broadening infection protection

...PNAG (dPNAG) elicited bacteria-killing antibodies in mice. 6,11 His teams also developed a human mAb-dubbed F598...
...Vlock said. In 2010, Sanofi exercised an option from Alopexx Pharmaceuticals to in-license F598 ( SAR279356...
...PNAG-expressing pathogens identified in ref. 1. BKey illnesses associated with the pathogen. CPathogens that F598 (SAR279356...
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

...N. meningitidis, S. pneumoniae, S. pyogenes or P. burghei infection, pretreatment with the anti-PNAG antibody F598...
...and markers of disease compared with control antibody or control serum. Ongoing work includes testing F598...
...Streptococcus and other pathogens that cause neonatal infections. Alopexx Pharmaceuticals LLC and Sanofi have F598 (SAR279356...
BioCentury | Apr 2, 2012
Emerging Company Profile

Arsanis: Antibodies for infection

...anti-infectious antibodies. In 2010, Sanofi entered three deals for antibodies to treat infectious diseases, licensing SAR279356...
...LLC , KB001 from KaloBios Pharmaceuticals Inc. and the VivaScreen discovery technology from Vivalis S.A. SAR279356...
BioCentury | Dec 14, 2009
Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

...Alopexx granted sanofi-aventis an option to license exclusive, worldwide rights to F598 . The mAb against...
BioCentury | Dec 11, 2009
Company News

sanofi receives option to Alopexx mAb

...Cambridge, Mass.) granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) an option to license exclusive, worldwide rights to F598...
Items per page:
1 - 7 of 7